Table 1.
Baseline characteristics of men and women with atherosclerotic cardiovascular disease.
| Characteristics | ASCVD |
||||
|---|---|---|---|---|---|
| Total Population, n(%) | 97,819 |
||||
| Sample by Gender, n (%) | Men |
Women |
p value | ||
| N | % | N | % | ||
| 54,142 | 55.3 % | 43,677 | 44.7 % | ||
| Age Group (years) | |||||
| <45 | 1741 | 3.2 % | 1822 | 4.2 % | <0.001 |
| 45–64 | 15,703 | 29.0 % | 10,931 | 25.0 % | |
| >=65 | 36,698 | 67.8 % | 30,924 | 70.8 % | |
| Race-Ethnicity | |||||
| Non Hispanic White | 35,907 | 66.3 % | 26,608 | 60.9 % | 0.1226 |
| Non Hispanic Black | 6279 | 11.6 % | 8455 | 19.4 % | |
| Non Hispanic Asian | 3409 | 6.3 % | 2142 | 4.9 % | |
| Non Hispanic Other | 1251 | 2.3 % | 738 | 1.7 % | |
| Hispanics | 6293 | 11.6 % | 5052 | 11.6 % | |
| Unknown Race/Ethnicity | 1003 | 1.9 % | 682 | 1.6 % | |
| Texas State ADI Quintiles | |||||
| Quintile 1 (least deprived) | 14,343 | 26.5 % | 9990 | 22.9 % | <0.001 |
| Quintile 2 | 15,033 | 27.8 % | 11,620 | 26.6 % | |
| Quintile 3 | 10,467 | 19.3 % | 8950 | 20.5 % | |
| Quintile 4 | 8043 | 14.9 % | 7138 | 16.3 % | |
| Quintile 5 (most deprived) | 5214 | 9.6 % | 5112 | 11.7 % | |
| ADI N/A | 1042 | 1.9 % | 867 | 2.0 % | |
| Insurance | |||||
| Public | 32,449 | 59.9 % | 29,068 | 66.6 % | <0.001 |
| Private | 14,173 | 26.2 % | 9816 | 22.5 % | |
| Uninsured or Other or NA | 5285 | 9.8 % | 3171 | 7.3 % | |
| Self-Pay | 2235 | 4.1 % | 1622 | 3.7 % | |
| BMI >30 kg/m2 | |||||
| Obesity | 22,080 | 17,843 | |||
| Obese Class 1+ | 12,698 | 57.5 % | 8753 | 49.1 % | <0.001 |
| Obese Class 2+ | 6991 | 31.7 % | 5826 | 32.7 % | |
| Obese Class 3+ | 2391 | 10.8 % | 3264 | 18.3 % | |
| Lipid Parameters (mean ± SD) | |||||
| LDL-C mg/dL (overall) | 81.4 ± 35.6 | 92.5 ± 38.9 | |||
| HDL-C mg/dL | 45.4 ± 14.2 | 56.8 ± 17.7 | |||
| Triglycerides mg/dL | 130.2 ± 94.0 | 125.3 ± 83.1 | |||
| Lipoprotein A in mnol/dL | 81.6 ± 90.0 | 102.9 ± 113.9 | |||
| LDL-Cholesterol | 38,773 | 31,549 | |||
| <70 | 16,549 | 42.7 % | 9519 | 30.2 % | <0.001 |
| 70–99 | 12,474 | 32.2 % | 10,419 | 33.0 % | |
| 100–129 | 5877 | 15.2 % | 6463 | 20.5 % | |
| 130–159 | 2551 | 6.6 % | 3273 | 10.4 % | |
| 160–189 | 951 | 2.5 % | 1281 | 4.1 % | |
| >=190 | 371 | 1.0 % | 594 | 1.9 % | |
| Risk Factors | |||||
| Current Smoking | 4782 | 8.8 % | 3165 | 7.2 % | <0.001 |
| Hypertension | 49,008 | 90.5 % | 38,064 | 87.1 % | <0.001 |
| Diabetes Mellitus | 18,405 | 34.0 % | 13,126 | 30.1 % | <0.001 |
| Obesity | 20,052 | 37.0 % | 16,392 | 37.5 % | 0.1121 |
| Dyslipidemia | 29,721 | 54.9 % | 23,780 | 54.4 % | 0.1604 |
| Charlson comorbidity index | |||||
| 0 | 3902 | 7.2 % | 2105 | 4.8 % | <0.001 |
| 1 to 3 | 26,491 | 48.9 % | 22,609 | 51.8 % | |
| >=4 | 23,749 | 43.9 % | 18,963 | 43.4 % | |
| Comorbidities | |||||
| Renal Disease | 17,350 | 32.0 % | 12,261 | 28.1 % | <0.001 |
| COPD | 14,351 | 26.5 % | 14,909 | 34.1 % | <0.001 |
| Cancer | 9886 | 18.3 % | 7040 | 16.1 % | <0.001 |
| Heart Failure | 16,530 | 30.5 % | 12,125 | 27.8 % | <0.001 |
| Atrial Fibrillation | 14,756 | 27.3 % | 9505 | 21.8 % | <0.001 |
| Medication Use | |||||
| PCSK9i | 1141 | 2.1 % | 835 | 1.9 % | 0.0306 |
| Ezetimibe | 5718 | 10.6 % | 4155 | 9.5 % | <0.001 |
| Bempedoic Acid | 98 | 0.2 % | 94 | 0.2 % | 0.2294 |
| Icosapent Ethyl | 1612 | 3.0 % | 781 | 1.8 % | <0.001 |
| Fibric Acid Derivatives | 2554 | 4.7 % | 1220 | 2.8 % | <0.001 |
| Bile Acid Sequestrants | 351 | 0.6 % | 444 | 1.0 % | <0.001 |
| Chol Absorption Inhibs. | 4376 | 8.1 % | 2932 | 6.7 % | <0.001 |
| Aspirin | 31,799 | 58.7 % | 21,038 | 48.2 % | <0.001 |